Aducanumab-avwa (Aduhelm™)

Evicore does not recommend approval or coverage of aducanumab‑avwa (Aduhelm) due to insufficient evidence of clinically meaningful benefit and demonstrated safety concerns. If requested, use must be for the FDA‑approved indication (Alzheimer’s), initiated in patients with mild cognitive impairment or mild dementia as studied, and documented to meet specific coverage guidelines and applicable safety criteria.

"In the absence of additional clinical trials, there is not enough information to support approval."

Sign up to see full coverage criteria, indications, and limitations.